Crescent Biopharma CBIO Stock
15.89 USD
{{ price }}
2.219360%
{{change_pct}}%
SECTOR
Healthcare
INDUSTRY
Biotechnology
COUNTRY
United States
Exchange
NasdaqCM
Market Cap
309.86M USD
LOW - HIGH [24H]
15.5
-
16.24 USD
VOLUME [24H]
171.07K USD
{{ volume }}
P/E Ratio
0
Earnings per share
0 USD
Crescent Biopharma Price Chart
Crescent Biopharma CBIO Financial and Trading Overview
| Crescent Biopharma stock price | 15.89 USD |
| Previous Close | 0.23 USD |
| Open | 0.24 USD |
| Bid | 0 USD x 1800 |
| Ask | 0 USD x 4000 |
| Day's Range | 0.24 - 0.26 USD |
| 52 Week Range | 0.19 - 2.09 USD |
| Volume | 323.9K USD |
| Avg. Volume | 206.67K USD |
| Market Cap | 9.37M USD |
| Beta (5Y Monthly) | 1.193661 |
| PE Ratio (TTM) | 1.1819048 |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | January 13, 2023 |
| 1y Target Est | N/A |
CBIO Valuation Measures
| Enterprise Value | 33.89M USD |
| Trailing P/E | 1.1819048 |
| Forward P/E | -1.6546665 |
| PEG Ratio (5 yr expected) | 0.06 |
| Price/Sales (ttm) | Infinity |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -1.684 |
Trading Information
Crescent Biopharma Stock Price History
| Beta (5Y Monthly) | 1.193661 |
| 52-Week Change | -82.75% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.09 USD |
| 52 Week Low | 0.19 USD |
| 50-Day Moving Average | 0.22 USD |
| 200-Day Moving Average | 0.49 USD |
CBIO Share Statistics
| Avg. Volume (3 month) | 206.67K USD |
| Avg. Daily Volume (10-Days) | 175.75K USD |
| Shares Outstanding | 37.76M |
| Float | 27.23M |
| Short Ratio | 1.71 |
| % Held by Insiders | 28.19% |
| % Held by Institutions | 13.66% |
| Shares Short | 251.78K |
| Short % of Float | 0.67% |
| Short % of Shares Outstanding | 0.67% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -42.89% |
| Return on Equity (ttm) | 38.06% |
Income Statement
| Revenue (ttm) | 0 USD |
| Revenue Per Share (ttm) | 0 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -20133000 USD |
| Net Income Avi to Common (ttm) | 6.55M USD |
| Diluted EPS (ttm) | 0.21 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 8.1M USD |
| Total Cash Per Share (mrq) | 0.21 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 2.048 |
| Book Value Per Share (mrq) | -0.687 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -27262000 USD |
| Levered Free Cash Flow (ttm) | -19967124 USD |
Profile of Crescent Biopharma
| Country | United States |
| State | CA |
| City | South San Francisco |
| Address | 611 Gateway Blvd. |
| ZIP | 94080 |
| Phone | 650 871 0761 |
| Website | https://www.catalystbiosciences.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 7 |
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.
Q&A For Crescent Biopharma Stock
What is a current CBIO stock price?
Crescent Biopharma CBIO stock price today per share is 15.89 USD.
How to purchase Crescent Biopharma stock?
You can buy CBIO shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Crescent Biopharma?
The stock symbol or ticker of Crescent Biopharma is CBIO.
Which industry does the Crescent Biopharma company belong to?
The Crescent Biopharma industry is Biotechnology.
How many shares does Crescent Biopharma have in circulation?
The max supply of Crescent Biopharma shares is 19.5M.
What is Crescent Biopharma Price to Earnings Ratio (PE Ratio)?
Crescent Biopharma PE Ratio is now.
What was Crescent Biopharma earnings per share over the trailing 12 months (TTM)?
Crescent Biopharma EPS is 0 USD over the trailing 12 months.
Which sector does the Crescent Biopharma company belong to?
The Crescent Biopharma sector is Healthcare.
Crescent Biopharma CBIO included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 20601.1 USD — |
+1.02
|
5.72B USD — | 20480.2 USD — | 20624.5 USD — | — - | 5.72B USD — |
| NASDAQ Capital Market Composite RCMP | 121.8 USD — |
+3.17
|
— — | 118.74 USD — | 122.44 USD — | — - | — — |
| Nasdaq Health Care IXHC | 983.91 USD — |
+0.82
|
— — | 976.78 USD — | 985 USD — | — - | — — |
| NASDAQ Composite Total Return XCMP | 25259.83 USD — |
+1.03
|
— — | 25111.6 USD — | 25288.5 USD — | — - | — — |
- {{ link.label }} {{link}}